DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Ispinesib is an investigational drug.
There have been 15 clinical trials for Ispinesib. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2005.
The most common disease conditions in clinical trials are Precursor Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma, and Lymphoma, Extranodal NK-T-Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), GlaxoSmithKline, and NCIC Clinical Trials Group.
Recent Clinical Trials for Ispinesib
|A Study of Ispinesib in Metastatic Breast Cancer||Cytokinetics||Phase 1/Phase 2|
|Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma||National Cancer Institute (NCI)||Phase 1|
|Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer||National Cancer Institute (NCI)||Phase 2|